20.89

3.01% 0.61

After Hours: 21.80 0.91 +4.36%

Enliven Therapeutics Inc (ELVN)

Overview News Price History Option Chain Financials Discussions Forecast

Enliven Therapeutics Inc stock is traded at $20.89, with a volume of 143.66K. It is up +3.01% in the last 24 hours and down -4.61% over the past month. Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.

Previous Close:

$20.28

Open:

$20.23

24h Volume:

143.66K

Relative Volume:

0.66

Market Cap:

$1.02B

Revenue:

Net Income/Loss:

$-85.21M

P/E Ratio:

-11.05

EPS:

-1.89

Net Cash Flow:

$-68.53M

1W Performance:

-0.62%

1M Performance:

-4.61%

6M Performance:

-9.45%

1Y Performance:

+19.10%

1-Day Range:

$20.18

$21.18

1-Week Range:

$19.98

$22.21

52-Week Range:

$15.96

$30.03

Enliven Therapeutics Inc Stock (ELVN) Company Profile

Name

Enliven Therapeutics Inc

Sector

Healthcare (1171)

Industry

Biotechnology (670)

Phone

720-647-8519

Address

6200 LOOKOUT ROAD, BOULDER

Employee

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

ELVN's Discussions on Twitter

Compare ELVN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ELVN Enliven Therapeutics Inc	20.89	1.02B	0	-85.21M	-68.53M	-1.89
VRTX Vertex Pharmaceuticals Inc	512.52	131.61B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	672.36	73.51B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	619.97	37.67B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	253.44	32.81B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	266.26	28.62B	3.81B	-644.79M	-669.77M	-6.24

Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-13-24	Initiated	BTIG Research	Buy
Sep-09-24	Initiated	H.C. Wainwright	Buy
Jun-11-24	Initiated	Robert W. Baird	Outperform
Apr-09-24	Initiated	Mizuho	Buy
Mar-29-23	Initiated	Jefferies	Buy

Enliven Therapeutics Inc Stock (ELVN) Latest News

05:46 AM

Enliven Therapeutics CEO Samuel Kintz sells $260,320 in stock By Investing.com - Investing.com UK

05:46 AM

Mar 15, 2025

Decoding Enliven Therapeutics Inc (ELVN): A Strategic SWOT Insig - GuruFocus.com

Mar 15, 2025

Mar 14, 2025

Enliven grew fourth-quarter R&D spending with trials underway - BizWest

Mar 14, 2025

Enliven Therapeutics Stock (ELVN): Promising Advances in Oncology Pipeline - Value the Markets

Mar 14, 2025

Enliven Therapeutics Reports 2024 Financial Results - TipRanks

Mar 14, 2025

Mar 13, 2025

Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update - Citizentribune

Mar 13, 2025